{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-074730","form_type":"8-K","ticker":"INVA","cik":"0001080014","company_name":"Innoviva, Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.283907+00:00","generated_at":"2026-05-17T18:51:39.208699+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Innoviva Q2 2025 net income $63.7M; product sales up 54% YoY; zoliflodacin PDUFA Dec 15","bullets":["Q2 2025 net income $63.7M ($1.01 basic EPS) vs net loss of $34.7M in Q2 2024.","GSK royalty revenue $67.3M, flat YoY; IST U.S. net product sales $29.0M (+54% YoY).","ZEVTERA (ceftobiprole) commercially launched in U.S. July 2025 for three indications.","Zoliflodacin NDA accepted with Priority Review; PDUFA target date Dec 15, 2025; no AdCom planned.","Cash & equivalents $397.5M; strategic healthcare asset portfolio valued at $449.3M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-074730","json":"https://secwatch.observer/filing/0001104659-25-074730.json","markdown":"https://secwatch.observer/filing/0001104659-25-074730.md","text":"https://secwatch.observer/filing/0001104659-25-074730.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1080014/000110465925074730/0001104659-25-074730-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1080014/000110465925074730/tm2522376d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T18:51:39.208699+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}